The study, published in the Journal of Clinical Sleep Medicine by a team led by Julia T. Boyle of VA Boston Healthcare System and Harvard Medical School together with colleagues at Virginia Commonwealth University, Hangzhou Normal University, and the National Sleep Foundation, set out to answer a deceptively simple question. If you give someone a multidimensional sleep-health questionnaire, can that score reliably tell you whether they are also carrying a heavy load of insomnia symptoms? The question matters because sleep health and insomnia are conceptually distinct. Sleep health is typically framed as a positive construct, a constellation of dimensions such as regularity, satisfaction, alertness, timing, efficiency, and duration. Insomnia, by contrast, is a clinical syndrome defined by dissatisfaction with sleep quantity or quality, accompanied by daytime impairment. Yet the two constructs share obvious territory, and the new findings quantify just how much.

The Ru-SATED scale, developed from sleep-medicine pioneer Daniel Buysse’s influential 2014 framework, asks respondents about six domains: Regularity of sleep and wake times, Satisfaction with sleep, Alertness during the day, Timing of sleep, sleep Efficiency, and sleep Duration. Each domain is scored, producing a total that summarizes a person’s overall sleep health. Higher scores indicate healthier sleep. The instrument has been translated and validated across cultures, including a Chinese adaptation among healthcare students, and a recent psychometric and diagnostic evaluation in community-dwelling adults had already hinted that Ru-SATED scores could discriminate clinically relevant sleep problems. What remained unclear was precisely how well the scale performed as a detector of elevated insomnia symptoms in a large, diverse adult sample, and whether that performance held steady across demographic groups.

To find out, the researchers recruited 3,284 U.S. adults ranging in age from 19 to 99, with an average age of about 43 and roughly 45 percent male participants. Everyone completed online versions of two questionnaires: the Ru-SATED, capturing multidimensional sleep health, and the Insomnia Severity Index, or ISI, a widely used and extensively validated measure of insomnia symptom severity. The team defined elevated insomnia symptom burden as an ISI total score of 10 or higher, a threshold commonly used to flag individuals whose symptoms warrant clinical attention. The ISI has been validated in primary care populations, college students, adolescents, and numerous language versions, making its 10-point cutoff a well-anchored benchmark for the analysis.

The analytical engine of the study was receiver operating characteristic analysis, a statistical technique borrowed from signal detection theory and long used in clinical medicine to judge how well a test separates people who have a condition from people who do not. An ROC curve plots sensitivity, the true-positive rate, against the false-positive rate across every possible cutoff of the screening measure. The area under the curve, or AUC, summarizes overall discriminative ability: an AUC of 0.5 means the test performs no better than a coin flip, while an AUC of 1.0 means perfect separation. By sweeping through all possible Ru-SATED scores and measuring how accurately each one classified participants against the ISI threshold, the researchers could identify the optimal cutoff, along with the sensitivity, specificity, and accuracy at that cutoff.

The results were clear at the level of the whole sample. A Ru-SATED score of 8 or below showed the strongest signal detection performance for identifying elevated insomnia symptoms. In other words, when someone’s composite sleep-health score dipped to 8 or less out of the scale’s range, the probability that they were also reporting clinically meaningful insomnia symptoms rose sharply enough that the low sleep-health score functioned as an effective flag. The authors interpret this as evidence of criterion-related validity: the Ru-SATED does not merely describe sleep habits in the abstract, it carries real information about insomnia burden as measured against an established clinical yardstick.

But the story grew more interesting when the team ran exploratory subgroup analyses. The optimal cutoff was not universal. Among young adults, the strongest detection performance emerged at a lower score of 7 or below, suggesting that younger people may need a more pronounced dip in overall sleep health before the scale reliably flags insomnia symptoms. Among female participants, the opposite pattern appeared, with a higher cutoff of 9 or below performing best. These demographic shifts echo a broader literature documenting sex and age differences in insomnia. Insomnia symptoms are known to be more prevalent among women, and large school-based studies have traced the emergence of those sex differences in adolescence, while sleep architecture and insomnia presentation change across the lifespan in ways that could alter how sleep-health domains map onto insomnia complaints.

The implications cut in two directions. For researchers running population-based sleep-health studies, the findings are reassuring: the Ru-SATED is not blind to insomnia, and a low score is a meaningful warning sign that can be used to identify participants who may need closer clinical assessment. That makes the scale attractive for large surveys, cohort studies, and digital screening platforms where administering a full insomnia battery to every respondent is impractical. At the same time, the subgroup results are a caution against one-size-fits-all cutoffs. A threshold of 8 may underperform in young adults and miss cases among women if applied without adjustment, and the authors emphasize that unique populations deserve special attention when these tools are deployed.

There is also a deeper conceptual takeaway. The fact that a sleep-health scale detects insomnia symptoms at all confirms what many sleep scientists have suspected: the boundary between positive sleep health and insomnia pathology is porous. The six Ru-SATED domains, particularly satisfaction and efficiency, overlap directly with the core complaints of insomnia disorder as defined in the DSM-5 and the International Classification of Sleep Disorders. A person who is dissatisfied with their sleep and inefficient at sustaining it will score poorly on both constructs. The study does not claim the Ru-SATED can diagnose insomnia, and the authors frame their results as evidence of signal detection rather than diagnostic performance, but the demonstration that the scale’s scores contain an insomnia-related signal strengthens the case for treating sleep health as a continuum that shades into clinical disorder.

Funded in part by the National Institute on Aging and supported by resources of VA Boston Healthcare System, the study arrives at a moment of growing interest in sleep as a modifiable pillar of public health, alongside diet and exercise. Roughly a third of adults report insomnia symptoms at some point, and untreated insomnia carries costs ranging from impaired cognition and mood disorders to cardiovascular and metabolic disease. Simple, validated instruments that can be deployed at scale, and whose scoring quirks across age and sex are now better understood, are exactly the kind of infrastructure that population sleep science needs. The Ru-SATED, this research suggests, is more than a wellness checklist. Buried inside its tidy six-domain score is a genuine signal of one of the world’s most common and most undertreated sleep disorders, and researchers now know where, and for whom, to listen for it.

Subject of Research: Signal detection performance of the Ru-SATED sleep health scale for identifying elevated insomnia symptoms in U.S. adults

Article Title: From sleep health to insomnia: signal detection performance of the Ru-SATED scale

Article References: Boyle, J. T., Nielson, S. A., Xu, J., Meng, R., Zhang, J., & Dzierzewski, J. M. (2026). From sleep health to insomnia: signal detection performance of the Ru-SATED scale. Journal of Clinical Sleep Medicine, 22(1), Article 116. https://doi.org/10.1007/s44470-026-00126-3

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00126-3

Keywords: sleep health, insomnia, Ru-SATED, Insomnia Severity Index, ROC analysis, signal detection, criterion-related validity, sleep medicine, psychometrics, screening, sex differences, aging

The study, led by Zihang Tong and colleagues at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, pooled evidence from 96 randomized controlled trials encompassing 18,419 adult participants. The research team searched PubMed, the Cochrane Library, Embase, and Web of Science through October 2025, then used network meta-analysis — a statistical framework that combines both direct comparisons between treatments and indirect comparisons linked through a common control — to rank six digital interventions: digital cognitive behavioral therapy (dCBT), digital mindfulness-based therapy (dMBT), digital brief behavioral therapy (dBBT), circadian rhythm support (CRS), virtual reality (VR), and tele-neurofeedback (NFB). By folding every trial into a single evidence network anchored on a shared control node, the method allows treatments never tested against each other in the same trial to be compared with remarkable statistical efficiency.

The headline finding concerns the Insomnia Severity Index, or ISI, a seven-item questionnaire that scores insomnia symptoms from 0 to 28. Compared with control treatment, dCBT reduced ISI scores by an average of 4.24 points, with a 95 percent confidence interval of −4.83 to −3.65 — an estimate supported by moderate-certainty evidence under the CINeMA framework. That figure is not just statistically significant; it crosses the minimal clinically important difference, the threshold — set at 4 points for the ISI in this analysis — beyond which patients and clinicians should actually notice a change. In other words, dCBT is the only intervention in the network whose effect on the core outcome of insomnia severity was unambiguously meaningful for real patients.

The detailed picture across other outcomes is more nuanced. dCBT also significantly improved PSQI scores (a reduction of 2.28 points), shortened subjective sleep onset latency by about 12.6 minutes, raised subjective sleep efficiency by 7.27 percentage points, and cut subjective wake after sleep onset by roughly 17.2 minutes. Yet none of these secondary effects reached their respective minimal clinically important differences, which the authors defined as, for example, at least a 3-point PSQI change or a 20-minute reduction in latency. Digital mindfulness-based therapy produced a smaller but significant ISI reduction of 2.28 points and shortened objectively measured sleep onset latency by 7.96 minutes, the latter based on moderate-certainty evidence from polysomnography and actigraphy studies. Virtual reality, evaluated through an inconsistency model because of statistical heterogeneity, reduced objectively measured wake after sleep onset by 13.38 minutes — significant, but again below the clinical threshold.

Direct head-to-head comparisons within the network reinforced dCBT’s dominance. It outperformed dMBT on the ISI (by 1.96 points) and on subjective total sleep time (by about 10 minutes), beat VR on the PSQI, and surpassed circadian rhythm support on sleep latency and sleep efficiency measures. Using SUCRA statistics, which express the probability that a treatment ranks best, dCBT topped the charts for the ISI (93.3 percent), the PSQI (95.8 percent), subjective sleep onset latency (95.0 percent), and subjective sleep efficiency (93.0 percent). Three interventions — tele-neurofeedback, digital brief behavioral therapy, and circadian rhythm support — showed no statistically significant benefits over control for any outcome, effectively dropping out of the clinical conversation until better evidence emerges.

The authors went well beyond the headline averages. Subgroup analyses probed whether effects differed by control group type, therapist guidance, treatment duration, and population. Notably, dCBT performed as well as face-to-face CBT where such comparisons existed, held up against active controls rather than only passive waitlists, and worked whether delivered with a therapist in the loop or fully automated — the ISI effect was −4.48 points with guidance versus −4.10 points without, a gap of less than half a point. Treatment duration mattered little for the core outcome: the ISI effect was identical (−4.24 points) whether programs ran eight weeks or longer. Effects were somewhat larger in people with insomnia symptoms who lack a formal diagnosis than in diagnosed patients, suggesting those with less entrenched sleep pathology may respond more readily to structured digital programs.

Sensitivity analyses added important caveats about who benefits. dCBT’s effects proved stable across pregnant women, cancer patients, and people with depression or anxiety, indicating broad applicability. dMBT’s efficacy, by contrast, appeared inflated in pregnant women under certain control designs and weaker in cancer survivors, and its improvement on the PSQI was fragile among depressed patients. VR was the most volatile intervention of all: its estimated effects swung dramatically depending on which small studies were included, leading the authors to urge caution about deploying VR in oncology, acute medical settings, and populations with severe somatic disease.

The study is candid about its limitations, and readers should absorb them. Only two of the 96 trials were judged low risk of bias overall, with 94 showing some concerns — especially around outcome measurement, where participants inevitably know what treatment they are receiving, inflating expectancy effects on subjective questionnaires. Heterogeneity was high for the ISI and PSQI, objective sleep outcomes rested on few trials with small samples, roughly 40 trials had potential industry funding, and the analysis captured only immediate post-treatment results with no follow-up data on whether benefits persist. The treatment taxonomy also followed a Chinese expert consensus rather than international regulatory frameworks, which may limit direct comparability with other classification schemes.

Still, the practical implications are hard to escape. For clinicians building insomnia care pathways, the evidence reasonably supports dCBT as the primary digital option, given its clinically meaningful reduction in insomnia severity. dMBT emerges as a reasonable alternative or adjunct — particularly for patients who prefer mindfulness approaches or struggle to adhere to CBT — even though its benefits did not reach clinical significance thresholds. The absence of patient and public involvement in the analysis, the authors acknowledge, means real-world preferences around acceptability remain underexplored. What the study delivers is something prior reviews could not: a single network in which six different digital therapies, from smartphone-delivered CBT to immersive VR, compete on equal statistical footing to answer the question patients actually ask — which one is best.

The research team, funded by Tianjin science and health programs and registered prospectively on PROSPERO, concludes that future work should prioritize large-scale, high-quality randomized trials with standardized interventions, objective outcome frameworks, and long-term follow-up. Until then, this analysis stands as the most complete map of the digital sleep-therapy landscape — one that confirms the promise of treatment delivered by app, but also warns that statistical significance alone is not the same as a patient sleeping meaningfully better. For the 16.2 percent of adults worldwide reporting clinically significant insomnia, the difference between those two thresholds is exactly the kind of precision that evidence-based medicine is meant to provide.

Subject of Research: Comparative effectiveness of digital therapeutics for improving sleep quality in adults with insomnia

Article Title: The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis

Article References: Tong, Z., Ye, G., Fan, S., Li, Y., Zhang, J., Zhang, H., Chen, Q., Wang, H., Li, H., & Wang, J. (2026). The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis. BMC Medicine, 24(1), Article 526. https://doi.org/10.1186/s12916-026-05129-8

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05129-8

Keywords: digital therapeutics, insomnia, sleep quality, network meta-analysis, digital cognitive behavioral therapy, mindfulness, virtual reality, tele-neurofeedback, circadian rhythm support, randomized controlled trials, PSQI, Insomnia Severity Index

The investigation drew on data from the National Health and Resilience in Veterans Study, a rigorously conducted survey designed to reflect the demographic composition of the roughly 20 million adults who have served in the U.S. armed forces. Participants completed the Insomnia Severity Index, a validated seven-item instrument that quantifies the severity of nighttime sleep complaints—difficulty falling asleep, staying asleep, and waking too early—together with daytime impairment, distress, and dissatisfaction with sleep. Using established clinical cutoffs, the researchers classified veterans scoring 15 or higher as having clinical insomnia, while scores between 8 and 14 defined subthreshold insomnia, a state of clinically meaningful but subdiagnostic sleep disturbance. This two-tiered approach matters because much of the public health burden of poor sleep is carried not by those with formal diagnoses but by the much larger group hovering just below the diagnostic threshold.

Technically, the Insomnia Severity Index offers advantages over simpler sleep questionnaires because it captures both the objective dimensions of sleep disruption and the subjective suffering and functional impairment that accompany it. Cutoffs of 8 and 15 were validated against clinical interviews and treatment response studies, giving epidemiologists a reproducible way to stratify populations. In the new study, the proportion of veterans in the clinical range—13.6 percent—represents a relative increase of nearly 20 percent over the pre-pandemic estimate, while subthreshold insomnia rose by almost four percentage points. Combined, more than 43 percent of the veteran population now reports sleep disturbance at a level associated with impaired daytime functioning, a figure the authors describe as a substantial and growing public health concern for a population already at elevated risk for psychiatric illness and suicide.

Who is most affected? The demographic and clinical profile of veterans with insomnia is strikingly consistent across severity levels. Those with clinical and subthreshold insomnia were younger on average than their well-rested peers, more likely to belong to racial and ethnic minority groups, and disproportionately burdened by adversity. They reported greater lifetime exposure to traumatic events, higher rates of military sexual trauma, and elevated levels of homelessness, alongside a heavier load of chronic medical conditions. Each of these factors is well established in the sleep literature as a driver of hyperarousal—the physiological state of heightened vigilance that interferes with sleep initiation and maintenance—and their concentration among veterans with insomnia underscores how sleep disturbance often functions as a barometer of accumulated biological and psychosocial stress.

The strongest signal in the study, however, lies in the association between insomnia severity and mental health outcomes. After statistical adjustment for age, race and ethnicity, trauma exposure, medical burden, and other confounding characteristics, subthreshold insomnia was associated with two- to six-fold greater odds of depression, anxiety, PTSD, and suicidal ideation. Clinical insomnia carried an even heavier burden: two- to twelve-fold greater odds of these outcomes, including nearly four-fold greater odds of future suicidal intent. Suicidal intent—a construct reflecting not just passive thoughts of death but active planning or preparation—is among the most proximal predictors of suicide attempt, making the nearly four-fold elevation in this outcome particularly consequential for suicide prevention efforts within the Veterans Health Administration and beyond.

These dose-response patterns reinforce a growing body of evidence that insomnia is not merely a symptom that rides along with psychiatric illness but an active, transdiagnostic risk factor in its own right. Longitudinal and meta-analytic work has shown that insomnia predicts the onset of depression, anxiety disorders, and substance misuse in community and clinical samples, and prior research in veterans specifically has demonstrated that poor self-rated sleep quality prospectively predicts new-onset suicidal ideation over multi-year follow-up. Mechanistically, researchers point to shared pathways: chronic sleep fragmentation disrupts emotional regulation circuits in the prefrontal cortex and amygdala, impairs cognitive control, heightens inflammatory signaling, and deepens the hopelessness and social withdrawal that characterize suicidal states. Sleep, in this framing, is a modifiable upstream lever with downstream consequences for virtually the entire spectrum of psychiatric morbidity.

The temporal comparison embedded in the study adds an important epidemiological dimension. By anchoring the new prevalence estimates to a nationally representative veteran sample surveyed in 2019–2020, the researchers could quantify change across a period that included the acute and sustained disruptions of the COVID-19 pandemic. Previous prospective work in the same veteran population documented substantial new-onset and worsening insomnia symptoms during the pandemic, and global meta-analyses have confirmed elevated rates of sleep problems, particularly among women and those under pandemic-related stress. The new findings suggest that the pandemic-era surge in disturbed sleep did not simply rebound once restrictions eased; instead, a meaningful fraction of veterans appear to have crossed thresholds into clinically significant, persistent insomnia, consistent with the natural history of insomnia as a condition that, once entrenched, tends to follow a chronic and relapsing course without targeted treatment.

Importantly, effective treatment exists. Cognitive behavioral therapy for insomnia, or CBT-I, is the first-line, evidence-based intervention, producing durable improvements in sleep onset, sleep maintenance, and sleep-related distress without the dependence risks and next-day impairment associated with chronic hypnotic use. Recent randomized trials in veteran populations have strengthened the case further: brief CBT-I delivered in primary care has been tested in veterans at elevated suicide risk, and integrated protocols combining CBT-I with trauma-focused therapies such as prolonged exposure have outperformed sleep-hygiene education in veterans with comorbid PTSD. The authors argue that the sheer size of the subthreshold group—nearly a third of all veterans—creates a compelling case for early identification and intervention before sleep disturbance consolidates into full clinical insomnia and its associated psychiatric consequences.

For clinicians and health systems, the practical implications are concrete. Routine screening with the Insomnia Severity Index in veteran care settings could identify the large pool of veterans in the 8-to-14 range who are rarely captured by diagnosis-driven workflows but who carry two- to six-fold elevations in psychiatric risk. The study’s finding that insomnia clusters among younger veterans, racial and ethnic minority groups, and those with histories of military sexual trauma and homelessness also signals where outreach should be concentrated, particularly given documented disparities in access to behavioral sleep medicine. Obstructive sleep apnea, which is highly prevalent among veterans and frequently coexists with insomnia, warrants parallel evaluation so that comorbid sleep pathology is not missed. As the veteran population ages and the psychiatric and suicide burden of poor sleep becomes clearer, the authors conclude that treating insomnia—early, aggressively, and with evidence-based tools—should be regarded not as an ancillary service but as a core strategy for reducing psychiatric morbidity and suicide risk in those who have served.

Subject of Research: Prevalence and mental health burden of clinical and subthreshold insomnia in U.S. military veterans.

Article Title: Clinical and subthreshold insomnia in U.S. veterans: increasing prevalence and mental health burden

Article References: Pietrzak, R. H., Fischer, I. C., McCarthy, E., DeViva, J. C., & Na, P. J. (2026). Clinical and subthreshold insomnia in U.S. veterans: increasing prevalence and mental health burden. Journal of Clinical Sleep Medicine, 22(1), Article 167. https://doi.org/10.1007/s44470-026-00143-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00143-2

Keywords: insomnia, veterans, sleep disorders, mental health, depression, PTSD, suicidal ideation, anxiety, Insomnia Severity Index, subthreshold insomnia, cognitive behavioral therapy, military sexual trauma